Identification of Clinical, Biological, Cellular and Genetic Markers of Favorable Response to Complement Inhibitors Therapy in Patients With Generalized Myasthenia Gravis

What this Trial Is About

Myasthenia gravis is an autoimmune neurological disease caused by antibodies attacking parts of the neuromuscular junction, especially the acetylcholine receptor (anti-AChR). This condition can lead to muscle weakness and other symptoms. Researchers are studying how different patients respond to complement inhibitor therapies, which target the immune system component contributing to this disease. The goal is to identify clinical, biological, cellular, and genetic markers that predict which patients will benefit most from these treatments. The study focuses on patients with generalized myasthenia gravis who are positive for anti-AChR antibodies and require treatment with complement inhibitors, as approved by regulatory authorities. No new drugs or treatments are administered in this observational study. Instead, patients will be followed while receiving complement inhibitor therapies prescribed according to standard medical guidelines. Participants in the study will undergo assessments over a 24-month period to collect clinical, biological, cellular, and genetic data. Researchers will analyze these data to find markers associated with favorable responses to complement inhibitors. The study also aims to develop a predictive algorithm to personalize treatment choices. Participants will be regularly monitored at the reference center, and their progress and response to therapy will be carefully documented throughout the study.

Markers of Favorable Response to Complement Inhibitors Therapy